BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. BCRX Peers
See (BCRX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BCRX | $10.59 | +1.92% | 2.2B | -40.73 | -$0.26 | N/A |
| VRTX | $436.00 | +0.45% | 112B | -113.54 | -$3.84 | N/A |
| REGN | $588.34 | -1.43% | 62.5B | 14.95 | $39.36 | +0.30% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $289.96 | +0.33% | 37.8B | -138.74 | -$2.09 | N/A |
| ARGX | $587.61 | +1.06% | 35.9B | 35.85 | $16.39 | N/A |
| BNTX | $98.68 | -0.39% | 23.7B | -27.34 | -$3.61 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| SMMT | $25.85 | +0.31% | 19.1B | -76.03 | -$0.34 | N/A |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
BCRX vs VRTX Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, VRTX has a market cap of 112B. Regarding current trading prices, BCRX is priced at $10.59, while VRTX trades at $436.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas VRTX's P/E ratio is -113.54. In terms of profitability, BCRX's ROE is +0.11%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, BCRX is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs REGN Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, REGN has a market cap of 62.5B. Regarding current trading prices, BCRX is priced at $10.59, while REGN trades at $588.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas REGN's P/E ratio is 14.95. In terms of profitability, BCRX's ROE is +0.11%, compared to REGN's ROE of +0.15%. Regarding short-term risk, BCRX is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs SGEN Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, BCRX is priced at $10.59, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas SGEN's P/E ratio is -57.19. In terms of profitability, BCRX's ROE is +0.11%, compared to SGEN's ROE of -0.17%. Regarding short-term risk, BCRX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs ALNY Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, ALNY has a market cap of 37.8B. Regarding current trading prices, BCRX is priced at $10.59, while ALNY trades at $289.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas ALNY's P/E ratio is -138.74. In terms of profitability, BCRX's ROE is +0.11%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, BCRX is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs ARGX Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, ARGX has a market cap of 35.9B. Regarding current trading prices, BCRX is priced at $10.59, while ARGX trades at $587.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas ARGX's P/E ratio is 35.85. In terms of profitability, BCRX's ROE is +0.11%, compared to ARGX's ROE of +0.16%. Regarding short-term risk, BCRX is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs BNTX Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, BNTX has a market cap of 23.7B. Regarding current trading prices, BCRX is priced at $10.59, while BNTX trades at $98.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas BNTX's P/E ratio is -27.34. In terms of profitability, BCRX's ROE is +0.11%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, BCRX is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs BGNE Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, BCRX is priced at $10.59, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas BGNE's P/E ratio is -22.55. In terms of profitability, BCRX's ROE is +0.11%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, BCRX is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs SMMT Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, SMMT has a market cap of 19.1B. Regarding current trading prices, BCRX is priced at $10.59, while SMMT trades at $25.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas SMMT's P/E ratio is -76.03. In terms of profitability, BCRX's ROE is +0.11%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, BCRX is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs DNA-WT Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, BCRX is priced at $10.59, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, BCRX's ROE is +0.11%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, BCRX is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for BCRX.
BCRX vs RPRX Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, RPRX has a market cap of 18.2B. Regarding current trading prices, BCRX is priced at $10.59, while RPRX trades at $32.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas RPRX's P/E ratio is 13.24. In terms of profitability, BCRX's ROE is +0.11%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, BCRX is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs UTHR Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, UTHR has a market cap of 13.9B. Regarding current trading prices, BCRX is priced at $10.59, while UTHR trades at $307.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas UTHR's P/E ratio is 12.26. In terms of profitability, BCRX's ROE is +0.11%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, BCRX is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs GMAB Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, GMAB has a market cap of 12.8B. Regarding current trading prices, BCRX is priced at $10.59, while GMAB trades at $20.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas GMAB's P/E ratio is 12.24. In terms of profitability, BCRX's ROE is +0.11%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, BCRX is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs KRTX Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, BCRX is priced at $10.59, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas KRTX's P/E ratio is -28.09. In terms of profitability, BCRX's ROE is +0.11%, compared to KRTX's ROE of -0.25%. Regarding short-term risk, BCRX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs INCY Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, INCY has a market cap of 12.4B. Regarding current trading prices, BCRX is priced at $10.59, while INCY trades at $64.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas INCY's P/E ratio is 321.23. In terms of profitability, BCRX's ROE is +0.11%, compared to INCY's ROE of +0.01%. Regarding short-term risk, BCRX is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs EXEL Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, EXEL has a market cap of 11.6B. Regarding current trading prices, BCRX is priced at $10.59, while EXEL trades at $42.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas EXEL's P/E ratio is 19.36. In terms of profitability, BCRX's ROE is +0.11%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, BCRX is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs BMRN Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, BMRN has a market cap of 11B. Regarding current trading prices, BCRX is priced at $10.59, while BMRN trades at $57.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas BMRN's P/E ratio is 21.31. In terms of profitability, BCRX's ROE is +0.11%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, BCRX is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs MRNA Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, MRNA has a market cap of 10.2B. Regarding current trading prices, BCRX is priced at $10.59, while MRNA trades at $26.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas MRNA's P/E ratio is -3.01. In terms of profitability, BCRX's ROE is +0.11%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, BCRX is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs ASND Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, ASND has a market cap of 9.8B. Regarding current trading prices, BCRX is priced at $10.59, while ASND trades at $162.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas ASND's P/E ratio is -24.62. In terms of profitability, BCRX's ROE is +0.11%, compared to ASND's ROE of +1.91%. Regarding short-term risk, BCRX is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for BCRX.
BCRX vs RXDX Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, BCRX is priced at $10.59, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas RXDX's P/E ratio is -56.47. In terms of profitability, BCRX's ROE is +0.11%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, BCRX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs IMGN Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, BCRX is priced at $10.59, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas IMGN's P/E ratio is -111.55. In terms of profitability, BCRX's ROE is +0.11%, compared to IMGN's ROE of +0.05%. Regarding short-term risk, BCRX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs CORT Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, CORT has a market cap of 8.3B. Regarding current trading prices, BCRX is priced at $10.59, while CORT trades at $78.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas CORT's P/E ratio is 68.43. In terms of profitability, BCRX's ROE is +0.11%, compared to CORT's ROE of +0.20%. Regarding short-term risk, BCRX is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for BCRX.
BCRX vs CERE Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, BCRX is priced at $10.59, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas CERE's P/E ratio is -16.47. In terms of profitability, BCRX's ROE is +0.11%, compared to CERE's ROE of -0.99%. Regarding short-term risk, BCRX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs ROIVW Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, BCRX is priced at $10.59, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, BCRX's ROE is +0.11%, compared to ROIVW's ROE of -0.02%. Regarding short-term risk, BCRX is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for BCRX.
BCRX vs ROIV Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, ROIV has a market cap of 7.8B. Regarding current trading prices, BCRX is priced at $10.59, while ROIV trades at $10.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas ROIV's P/E ratio is -10.87. In terms of profitability, BCRX's ROE is +0.11%, compared to ROIV's ROE of -0.02%. Regarding short-term risk, BCRX is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs RVMD Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, RVMD has a market cap of 7.4B. Regarding current trading prices, BCRX is priced at $10.59, while RVMD trades at $39.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas RVMD's P/E ratio is -9.92. In terms of profitability, BCRX's ROE is +0.11%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, BCRX is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for BCRX.
BCRX vs TECH Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, TECH has a market cap of 7.3B. Regarding current trading prices, BCRX is priced at $10.59, while TECH trades at $46.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas TECH's P/E ratio is 56.36. In terms of profitability, BCRX's ROE is +0.11%, compared to TECH's ROE of +0.06%. Regarding short-term risk, BCRX is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs HALO Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, HALO has a market cap of 6.7B. Regarding current trading prices, BCRX is priced at $10.59, while HALO trades at $54.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas HALO's P/E ratio is 14.51. In terms of profitability, BCRX's ROE is +0.11%, compared to HALO's ROE of +1.22%. Regarding short-term risk, BCRX is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs JAZZ Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, JAZZ has a market cap of 6.7B. Regarding current trading prices, BCRX is priced at $10.59, while JAZZ trades at $108.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas JAZZ's P/E ratio is 14.68. In terms of profitability, BCRX's ROE is +0.11%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, BCRX is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs RETA Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, BCRX is priced at $10.59, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas RETA's P/E ratio is -66.29. In terms of profitability, BCRX's ROE is +0.11%, compared to RETA's ROE of +0.47%. Regarding short-term risk, BCRX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs BPMC Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, BPMC has a market cap of 6.6B. Regarding current trading prices, BCRX is priced at $10.59, while BPMC trades at $101.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas BPMC's P/E ratio is -40.44. In terms of profitability, BCRX's ROE is +0.11%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, BCRX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs VRNA Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, VRNA has a market cap of 6.4B. Regarding current trading prices, BCRX is priced at $10.59, while VRNA trades at $75.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas VRNA's P/E ratio is -37.53. In terms of profitability, BCRX's ROE is +0.11%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, BCRX is less volatile compared to VRNA. This indicates potentially lower risk in terms of short-term price fluctuations for BCRX.
BCRX vs BBIO Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, BBIO has a market cap of 6.3B. Regarding current trading prices, BCRX is priced at $10.59, while BBIO trades at $33.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas BBIO's P/E ratio is -9.37. In terms of profitability, BCRX's ROE is +0.11%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, BCRX is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs MDGL Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, MDGL has a market cap of 5.9B. Regarding current trading prices, BCRX is priced at $10.59, while MDGL trades at $267.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas MDGL's P/E ratio is -14.99. In terms of profitability, BCRX's ROE is +0.11%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, BCRX is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs TLX Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, TLX has a market cap of 5.6B. Regarding current trading prices, BCRX is priced at $10.59, while TLX trades at $16.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas TLX's P/E ratio is 184.44. In terms of profitability, BCRX's ROE is +0.11%, compared to TLX's ROE of +0.14%. Regarding short-term risk, BCRX is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for BCRX.
BCRX vs ABCM Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, BCRX is priced at $10.59, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, BCRX's ROE is +0.11%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, BCRX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs ISEE Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, BCRX is priced at $10.59, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas ISEE's P/E ratio is -22.44. In terms of profitability, BCRX's ROE is +0.11%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, BCRX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs TGTX Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, TGTX has a market cap of 5.5B. Regarding current trading prices, BCRX is priced at $10.59, while TGTX trades at $34.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas TGTX's P/E ratio is 138.28. In terms of profitability, BCRX's ROE is +0.11%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, BCRX is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs NUVL Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, NUVL has a market cap of 5.3B. Regarding current trading prices, BCRX is priced at $10.59, while NUVL trades at $73.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas NUVL's P/E ratio is -16.63. In terms of profitability, BCRX's ROE is +0.11%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, BCRX is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs IONS Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, IONS has a market cap of 5.2B. Regarding current trading prices, BCRX is priced at $10.59, while IONS trades at $32.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas IONS's P/E ratio is -11.03. In terms of profitability, BCRX's ROE is +0.11%, compared to IONS's ROE of -0.00%. Regarding short-term risk, BCRX is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs AXSM Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, AXSM has a market cap of 5.2B. Regarding current trading prices, BCRX is priced at $10.59, while AXSM trades at $105.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas AXSM's P/E ratio is -18.21. In terms of profitability, BCRX's ROE is +0.11%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, BCRX is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs ADMA Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, ADMA has a market cap of 4.9B. Regarding current trading prices, BCRX is priced at $10.59, while ADMA trades at $20.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas ADMA's P/E ratio is 24.31. In terms of profitability, BCRX's ROE is +0.11%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, BCRX is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs ALKS Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, ALKS has a market cap of 4.8B. Regarding current trading prices, BCRX is priced at $10.59, while ALKS trades at $29.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas ALKS's P/E ratio is 13.98. In terms of profitability, BCRX's ROE is +0.11%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, BCRX is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs ALPN Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, BCRX is priced at $10.59, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas ALPN's P/E ratio is -101.52. In terms of profitability, BCRX's ROE is +0.11%, compared to ALPN's ROE of -0.15%. Regarding short-term risk, BCRX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs OPT Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, BCRX is priced at $10.59, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas OPT's P/E ratio is -1.52. In terms of profitability, BCRX's ROE is +0.11%, compared to OPT's ROE of +2.60%. Regarding short-term risk, BCRX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs PCVX Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, PCVX has a market cap of 4.2B. Regarding current trading prices, BCRX is priced at $10.59, while PCVX trades at $32.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas PCVX's P/E ratio is -8.16. In terms of profitability, BCRX's ROE is +0.11%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, BCRX is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for BCRX.
BCRX vs MRTX Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, BCRX is priced at $10.59, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas MRTX's P/E ratio is -4.82. In terms of profitability, BCRX's ROE is +0.11%, compared to MRTX's ROE of -0.40%. Regarding short-term risk, BCRX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs RYTM Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, RYTM has a market cap of 4B. Regarding current trading prices, BCRX is priced at $10.59, while RYTM trades at $62.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas RYTM's P/E ratio is -22.27. In terms of profitability, BCRX's ROE is +0.11%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, BCRX is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs SLNO Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, SLNO has a market cap of 3.9B. Regarding current trading prices, BCRX is priced at $10.59, while SLNO trades at $76.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas SLNO's P/E ratio is -16.22. In terms of profitability, BCRX's ROE is +0.11%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, BCRX is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for BCRX.
BCRX vs MRUS Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, MRUS has a market cap of 3.8B. Regarding current trading prices, BCRX is priced at $10.59, while MRUS trades at $55.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas MRUS's P/E ratio is -13.25. In terms of profitability, BCRX's ROE is +0.11%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, BCRX is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for BCRX.
BCRX vs RYZB Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, BCRX is priced at $10.59, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas RYZB's P/E ratio is -57.86. In terms of profitability, BCRX's ROE is +0.11%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, BCRX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs CBAY Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, BCRX is priced at $10.59, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas CBAY's P/E ratio is -32.81. In terms of profitability, BCRX's ROE is +0.11%, compared to CBAY's ROE of -0.32%. Regarding short-term risk, BCRX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs SRPT Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, SRPT has a market cap of 3.7B. Regarding current trading prices, BCRX is priced at $10.59, while SRPT trades at $37.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas SRPT's P/E ratio is -14.36. In terms of profitability, BCRX's ROE is +0.11%, compared to SRPT's ROE of -0.20%. Regarding short-term risk, BCRX is more volatile compared to SRPT. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs AKRO Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, AKRO has a market cap of 3.7B. Regarding current trading prices, BCRX is priced at $10.59, while AKRO trades at $46.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas AKRO's P/E ratio is -12.36. In terms of profitability, BCRX's ROE is +0.11%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, BCRX is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for BCRX.
BCRX vs RNA Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, RNA has a market cap of 3.7B. Regarding current trading prices, BCRX is priced at $10.59, while RNA trades at $30.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas RNA's P/E ratio is -10.19. In terms of profitability, BCRX's ROE is +0.11%, compared to RNA's ROE of -0.27%. Regarding short-term risk, BCRX is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs ACAD Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, BCRX is priced at $10.59, while ACAD trades at $21.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas ACAD's P/E ratio is 16.04. In terms of profitability, BCRX's ROE is +0.11%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, BCRX is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs CYTK Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, CYTK has a market cap of 3.6B. Regarding current trading prices, BCRX is priced at $10.59, while CYTK trades at $30.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas CYTK's P/E ratio is -5.77. In terms of profitability, BCRX's ROE is +0.11%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, BCRX is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs PTCT Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, PTCT has a market cap of 3.6B. Regarding current trading prices, BCRX is priced at $10.59, while PTCT trades at $45.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas PTCT's P/E ratio is 7.06. In terms of profitability, BCRX's ROE is +0.11%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, BCRX is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs KRYS Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, KRYS has a market cap of 3.6B. Regarding current trading prices, BCRX is priced at $10.59, while KRYS trades at $125.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas KRYS's P/E ratio is 30.06. In terms of profitability, BCRX's ROE is +0.11%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, BCRX is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs ACLX Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, ACLX has a market cap of 3.5B. Regarding current trading prices, BCRX is priced at $10.59, while ACLX trades at $63.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas ACLX's P/E ratio is -21.38. In terms of profitability, BCRX's ROE is +0.11%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, BCRX is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs SWTX Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, BCRX is priced at $10.59, while SWTX trades at $46.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas SWTX's P/E ratio is -13.63. In terms of profitability, BCRX's ROE is +0.11%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, BCRX is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs RARE Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, RARE has a market cap of 3.4B. Regarding current trading prices, BCRX is priced at $10.59, while RARE trades at $35.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas RARE's P/E ratio is -6.12. In terms of profitability, BCRX's ROE is +0.11%, compared to RARE's ROE of -1.86%. Regarding short-term risk, BCRX is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs CRSP Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, CRSP has a market cap of 3.2B. Regarding current trading prices, BCRX is priced at $10.59, while CRSP trades at $36.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas CRSP's P/E ratio is -8.21. In terms of profitability, BCRX's ROE is +0.11%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, BCRX is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs VKTX Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, VKTX has a market cap of 3B. Regarding current trading prices, BCRX is priced at $10.59, while VKTX trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas VKTX's P/E ratio is -23.26. In terms of profitability, BCRX's ROE is +0.11%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, BCRX is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs CPRX Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, CPRX has a market cap of 3B. Regarding current trading prices, BCRX is priced at $10.59, while CPRX trades at $24.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas CPRX's P/E ratio is 15.60. In terms of profitability, BCRX's ROE is +0.11%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, BCRX is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs MTSR Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, MTSR has a market cap of 2.9B. Regarding current trading prices, BCRX is priced at $10.59, while MTSR trades at $27.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas MTSR's P/E ratio is -10.75. In terms of profitability, BCRX's ROE is +0.11%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, BCRX is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for BCRX.
BCRX vs MORF Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, BCRX is priced at $10.59, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas MORF's P/E ratio is -14.88. In terms of profitability, BCRX's ROE is +0.11%, compared to MORF's ROE of -0.27%. Regarding short-term risk, BCRX is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs MOR Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, BCRX is priced at $10.59, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas MOR's P/E ratio is -12.64. In terms of profitability, BCRX's ROE is +0.11%, compared to MOR's ROE of +7.43%. Regarding short-term risk, BCRX is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs SRRK Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, SRRK has a market cap of 2.8B. Regarding current trading prices, BCRX is priced at $10.59, while SRRK trades at $30.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas SRRK's P/E ratio is -11.76. In terms of profitability, BCRX's ROE is +0.11%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, BCRX is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for BCRX.
BCRX vs PTGX Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, PTGX has a market cap of 2.8B. Regarding current trading prices, BCRX is priced at $10.59, while PTGX trades at $45.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas PTGX's P/E ratio is 58.54. In terms of profitability, BCRX's ROE is +0.11%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, BCRX is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs CRNX Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, CRNX has a market cap of 2.8B. Regarding current trading prices, BCRX is priced at $10.59, while CRNX trades at $29.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas CRNX's P/E ratio is -7.83. In terms of profitability, BCRX's ROE is +0.11%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, BCRX is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs KDNY Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, BCRX is priced at $10.59, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas KDNY's P/E ratio is -12.47. In terms of profitability, BCRX's ROE is +0.11%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, BCRX is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs LEGN Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, LEGN has a market cap of 2.7B. Regarding current trading prices, BCRX is priced at $10.59, while LEGN trades at $28.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas LEGN's P/E ratio is -24.50. In terms of profitability, BCRX's ROE is +0.11%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, BCRX is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs MYOV Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, BCRX is priced at $10.59, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas MYOV's P/E ratio is -14.05. In terms of profitability, BCRX's ROE is +0.11%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, BCRX is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs MLTX Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, MLTX has a market cap of 2.5B. Regarding current trading prices, BCRX is priced at $10.59, while MLTX trades at $38.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas MLTX's P/E ratio is -16.93. In terms of profitability, BCRX's ROE is +0.11%, compared to MLTX's ROE of -0.00%. Regarding short-term risk, BCRX is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs IMVT Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, IMVT has a market cap of 2.5B. Regarding current trading prices, BCRX is priced at $10.59, while IMVT trades at $14.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas IMVT's P/E ratio is -5.52. In terms of profitability, BCRX's ROE is +0.11%, compared to IMVT's ROE of -0.78%. Regarding short-term risk, BCRX is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs PRVB Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, BCRX is priced at $10.59, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas PRVB's P/E ratio is -16.43. In terms of profitability, BCRX's ROE is +0.11%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, BCRX is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs APGE Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, APGE has a market cap of 2.4B. Regarding current trading prices, BCRX is priced at $10.59, while APGE trades at $39.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas APGE's P/E ratio is -10.94. In terms of profitability, BCRX's ROE is +0.11%, compared to APGE's ROE of -0.19%. Regarding short-term risk, BCRX is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs LBPH Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, BCRX is priced at $10.59, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas LBPH's P/E ratio is -26.66. In terms of profitability, BCRX's ROE is +0.11%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, BCRX is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs AAPG Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, AAPG has a market cap of 2.3B. Regarding current trading prices, BCRX is priced at $10.59, while AAPG trades at $26.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas AAPG's P/E ratio is -35.78. In terms of profitability, BCRX's ROE is +0.11%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, BCRX is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for BCRX.
BCRX vs XENE Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, XENE has a market cap of 2.3B. Regarding current trading prices, BCRX is priced at $10.59, while XENE trades at $29.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas XENE's P/E ratio is -9.24. In terms of profitability, BCRX's ROE is +0.11%, compared to XENE's ROE of -0.32%. Regarding short-term risk, BCRX is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs DICE Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, BCRX is priced at $10.59, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas DICE's P/E ratio is -21.91. In terms of profitability, BCRX's ROE is +0.11%, compared to DICE's ROE of +0.56%. Regarding short-term risk, BCRX is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs IBRX Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, IBRX has a market cap of 2.2B. Regarding current trading prices, BCRX is priced at $10.59, while IBRX trades at $2.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas IBRX's P/E ratio is -4.44. In terms of profitability, BCRX's ROE is +0.11%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, BCRX is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for BCRX.
BCRX vs APLS Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, APLS has a market cap of 2.2B. Regarding current trading prices, BCRX is priced at $10.59, while APLS trades at $17.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas APLS's P/E ratio is -9.69. In terms of profitability, BCRX's ROE is +0.11%, compared to APLS's ROE of -1.00%. Regarding short-term risk, BCRX is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs MIRM Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, MIRM has a market cap of 2.2B. Regarding current trading prices, BCRX is priced at $10.59, while MIRM trades at $44.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas MIRM's P/E ratio is -27.33. In terms of profitability, BCRX's ROE is +0.11%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, BCRX is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs CALT Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, BCRX is priced at $10.59, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas CALT's P/E ratio is -22.73. In terms of profitability, BCRX's ROE is +0.11%, compared to CALT's ROE of -2.10%. Regarding short-term risk, BCRX is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for BCRX.
BCRX vs VCYT Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, VCYT has a market cap of 2.1B. Regarding current trading prices, BCRX is priced at $10.59, while VCYT trades at $27.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas VCYT's P/E ratio is 64.67. In terms of profitability, BCRX's ROE is +0.11%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, BCRX is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs ARWR Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, ARWR has a market cap of 2.1B. Regarding current trading prices, BCRX is priced at $10.59, while ARWR trades at $15.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas ARWR's P/E ratio is -12.20. In terms of profitability, BCRX's ROE is +0.11%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, BCRX is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs VCEL Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, VCEL has a market cap of 2.1B. Regarding current trading prices, BCRX is priced at $10.59, while VCEL trades at $40.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas VCEL's P/E ratio is 818.40. In terms of profitability, BCRX's ROE is +0.11%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, BCRX is more volatile compared to VCEL. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs BLTE Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, BLTE has a market cap of 2B. Regarding current trading prices, BCRX is priced at $10.59, while BLTE trades at $61.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas BLTE's P/E ratio is -44.85. In terms of profitability, BCRX's ROE is +0.11%, compared to BLTE's ROE of -0.31%. Regarding short-term risk, BCRX is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs NAMS Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, NAMS has a market cap of 2B. Regarding current trading prices, BCRX is priced at $10.59, while NAMS trades at $17.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas NAMS's P/E ratio is -9.57. In terms of profitability, BCRX's ROE is +0.11%, compared to NAMS's ROE of -0.26%. Regarding short-term risk, BCRX is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for BCRX.
BCRX vs NAMSW Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, NAMSW has a market cap of 2B. Regarding current trading prices, BCRX is priced at $10.59, while NAMSW trades at $8.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas NAMSW's P/E ratio is N/A. In terms of profitability, BCRX's ROE is +0.11%, compared to NAMSW's ROE of -0.26%. Regarding short-term risk, BCRX is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs KNSA Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, KNSA has a market cap of 2B. Regarding current trading prices, BCRX is priced at $10.59, while KNSA trades at $26.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas KNSA's P/E ratio is -112.04. In terms of profitability, BCRX's ROE is +0.11%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, BCRX is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for BCRX.
BCRX vs HRMY Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, HRMY has a market cap of 2B. Regarding current trading prices, BCRX is priced at $10.59, while HRMY trades at $34.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas HRMY's P/E ratio is 13.04. In terms of profitability, BCRX's ROE is +0.11%, compared to HRMY's ROE of +0.24%. Regarding short-term risk, BCRX is more volatile compared to HRMY. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs LGND Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, LGND has a market cap of 2B. Regarding current trading prices, BCRX is priced at $10.59, while LGND trades at $101.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas LGND's P/E ratio is -13.94. In terms of profitability, BCRX's ROE is +0.11%, compared to LGND's ROE of -0.16%. Regarding short-term risk, BCRX is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs DNLI Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, DNLI has a market cap of 1.9B. Regarding current trading prices, BCRX is priced at $10.59, while DNLI trades at $13.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas DNLI's P/E ratio is -5.03. In terms of profitability, BCRX's ROE is +0.11%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, BCRX is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs CGON Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, CGON has a market cap of 1.9B. Regarding current trading prices, BCRX is priced at $10.59, while CGON trades at $25.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas CGON's P/E ratio is -16.96. In terms of profitability, BCRX's ROE is +0.11%, compared to CGON's ROE of -0.17%. Regarding short-term risk, BCRX is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs KYMR Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, KYMR has a market cap of 1.9B. Regarding current trading prices, BCRX is priced at $10.59, while KYMR trades at $29.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas KYMR's P/E ratio is -9.48. In terms of profitability, BCRX's ROE is +0.11%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, BCRX is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs FOLD Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, FOLD has a market cap of 1.9B. Regarding current trading prices, BCRX is priced at $10.59, while FOLD trades at $6.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas FOLD's P/E ratio is -69.11. In terms of profitability, BCRX's ROE is +0.11%, compared to FOLD's ROE of -0.17%. Regarding short-term risk, BCRX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.
BCRX vs GLPG Comparison
BCRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BCRX stands at 2.2B. In comparison, GLPG has a market cap of 1.9B. Regarding current trading prices, BCRX is priced at $10.59, while GLPG trades at $28.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BCRX currently has a P/E ratio of -40.73, whereas GLPG's P/E ratio is -9.30. In terms of profitability, BCRX's ROE is +0.11%, compared to GLPG's ROE of -0.06%. Regarding short-term risk, BCRX is more volatile compared to GLPG. This indicates potentially higher risk in terms of short-term price fluctuations for BCRX.